Elocon

Legal status and availability in the UK

Elocon is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Elocon is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Elocon information

• INN (international nonproprietary name): Mometasone furoate
• Brand names available in the United Kingdom: Elocon (Organon); generic mometasone furoate
• ATC code: D07AC13 (Corticosteroids, potent, group III, for topical use)
• Forms and dosages: Cream 0.1% (15g, 30g tubes); Ointment 0.1% (15g, 30g tubes); Lotion 0.1% (30mL bottles)
• Manufacturers in the United Kingdom: Organon (original) and generic manufacturers
• Registration status in the United Kingdom: authorised by the MHRA; prescription-only topical corticosteroid; marketed formulations include cream, ointment and lotion
• OTC / Rx classification: Prescription-only medicine (POM)

Typical use and common issues

Elocon (mometasone furoate) is a commonly prescribed potent topical corticosteroid, available as the original product from Organon and as generic mometasone furoate.

Most patients notice symptom relief for eczema or dermatitis within a few days, but they also worry about steroid side effects such as skin thinning and hypopigmentation.

Common mistakes include prolonged use beyond the recommended 1–2 weeks, applying under occlusion without supervision, and using a strong steroid on the face or intertriginous areas.

Pharmacists verify the prescription, review the indication and give clear application instructions to reduce the risk of misuse.

What Elocon is: active ingredient and class

Core identity and classification

What exactly is Elocon?

Elocon is the brand name for products containing the INN mometasone furoate, a potent topical corticosteroid used for inflammatory skin conditions.

The ATC classification is D07AC13, indicating it is a potent group III topical corticosteroid.

Therapeutically it is a prescription topical steroid indicated for inflammatory dermatoses and is supplied in cream, ointment and lotion forms.

• INN: Mometasone furoate
• ATC code: D07AC13
• Therapeutic class: Potent topical corticosteroid
• Status: Prescription-only medicine (POM)

Forms, concentrations and packaging

Available dosage forms and strengths

Which preparation should be used for different skin areas?

Mometasone furoate is supplied typically as cream 0.1%, ointment 0.1% and lotion/solution 0.1% for scalp use.

Common pack sizes include 15g and 30g tubes for cream and ointment, and 30mL bottles for lotion.

Creams and lotions are generally preferred for eczematous and inflamed skin, while lotion or solution formulations suit scalp conditions where hair is present.

Indications

Licensed indications

When is dispensing Elocon appropriate?

Licensed uses include atopic dermatitis, eczema, psoriasis (site-limited), lichen planus and seborrhoeic dermatitis among other inflammatory dermatoses as per product information.

Pharmacists must confirm the prescription matches a licensed indication and that the patient understands where not to apply the product — it is not for ophthalmic, oral or intravaginal use.

For scalp conditions, the lotion/solution form is the usual choice and is typically applied once daily.

Off‑label uses and red flags

When should a pharmacist query or refuse supply?

Off‑label specialist uses do occur but require clear prescriber direction and supervision; pharmacists should be cautious about supplying for unconfirmed indications.

Do not supply if there are signs of untreated infection on the skin; topical steroids can worsen bacterial, viral or fungal infections unless those are being treated concurrently.

Avoid routine use on the face, groin or axillae unless the prescriber has explicitly advised it and documented monitoring plans.

How to use Elocon — dosing, frequency and practical tips

Typical application instructions

What is the usual advice to give patients?

Adults typically apply a thin layer of the cream or ointment to the affected area once daily.

Scalp solution or lotion is usually applied once daily to the affected scalp areas as directed.

Advise applying to clean, dry skin and avoiding occlusion unless the prescriber instructs otherwise because occlusion increases potency and systemic absorption.

Missed dose guidance: apply when remembered but do not double up doses.

Storage: keep at around 25°C with permitted excursions between 15–30°C, protect from freezing and keep the tube or bottle tightly closed.

• Clean and dry the area before application.
• Use a thin layer and rub in gently unless the prescriber specifies otherwise.
• Avoid applying to large surface areas, especially in children.
• Wash hands after application unless treating the hands.
• Do not cover with dressings unless advised by the prescriber.

Duration and follow‑up

How long should patients expect to use Elocon?

Acute flares are commonly treated for 1–2 weeks; longer courses should only be under clinical supervision.

For chronic conditions, the aim is the minimal effective frequency and duration with periodic review by the prescriber.

Children require shorter courses and careful monitoring because of higher systemic absorption risk; avoid use under 2 years and limit duration in toddlers when possible.

Pharmacists should flag repeat requests and recommend a GP or dermatology review if frequent courses are prescribed.

Efficacy and comparative clinical considerations

Potency and expected response

What can patients expect after starting treatment?

Mometasone furoate is a potent topical corticosteroid (group III) and often produces noticeable anti‑inflammatory effects within days.

Patients may report reduced redness and itching early on, while full resolution of lesions can take longer and depends on the underlying condition.

It is important to balance rapid symptom control with the risks of prolonged high‑potency steroid exposure.

Set realistic expectations: improvement within the first week is common, and clinical reassessment is appropriate at 1–2 weeks.

Comparators and when to choose Elocon

How does Elocon compare with other topical steroids?

Agents such as betamethasone and fluticasone occupy a similar potency band and may be used interchangeably depending on prescriber preference and availability.

Clobetasol is classed as superpotent and is reserved for short, severe flares; it is not a direct equivalent for routine moderate-to-severe lesions.

Choose Elocon when a potent steroid is appropriate for moderate-to-severe inflammatory lesions and when clinician guidance indicates its use over milder or superpotent options.

Side effects, monitoring and what to warn patients about

Common local adverse effects

What local reactions should patients expect or report?

Typical local side effects include mild burning or stinging at the application site, itching, dryness, folliculitis and acneiform eruptions.

Hypopigmentation and other changes in skin colour can occur, and prolonged or excessive use increases the risk of skin atrophy.

Systemic risks and red flags

Are there systemic effects from a topical steroid?

Systemic absorption is rare with appropriate topical use, but excessive use over large areas or under occlusion can suppress the hypothalamic–pituitary–adrenal axis and cause Cushingoid features.

Advise patients to stop and seek urgent medical review for signs such as unexpected weight gain, moon face, unusual bruising or severe lethargy.

Children are at greater risk of systemic effects and need dose and duration limits to reduce that risk.

Contraindications and cautions (absolute and relative)

Absolute contraindications

When must supply be refused?

Do not supply where there is known hypersensitivity to mometasone furoate or any excipients.

Also avoid use on skin with untreated bacterial, viral (for example herpes simplex, varicella), fungal or parasitic infections, and in conditions such as rosacea, acne vulgaris or perioral dermatitis.

• Hypersensitivity → do not supply; refer to GP.
• Active skin infection → treat infection first; do not supply until cleared or managed.
• Rosacea or perioral dermatitis → do not supply; refer to prescriber.

Relative cautions requiring monitoring

When should pharmacists exercise extra caution?

Use with caution in children, on extensive broken skin, during prolonged use or under occlusion, and in the elderly where skin thinning is a concern.

Pregnancy and lactation warrant a discussion of benefits versus risks and should generally be managed under medical supervision.

Record counselling and, where necessary, request prescriber guidance if the course exceeds typical duration or large areas are involved.

Use in special populations: children, pregnancy and elderly

Children

How do dosing and risks change for children?

Children are more susceptible to systemic absorption and skin atrophy, so mometasone is not recommended under 2 years and for children over 2 years courses should be as short as possible, usually less than three weeks when feasible.

Pharmacists should check age and weight where indicated and advise parents to use the minimal effective quantity and avoid occlusive dressings.

• Confirm age and indication at point of supply.
• Advise parents on amount to use (pea-sized amounts for small areas) and duration limits.
• Encourage follow-up with the prescriber if symptoms persist or recur.

Pregnancy, lactation and elderly

Can pregnant or breastfeeding patients use Elocon?

Topical mometasone should be used in pregnancy and lactation only if clearly needed and under medical supervision, weighing maternal benefit against potential risk.

In elderly patients increased monitoring for skin thinning and fragility is advised and use the lowest effective potency and duration.

Interactions and combination therapy

Topical combinations and phototherapy

Are there cautions when combining topical products?

Avoid using multiple topical steroid products together to prevent additive systemic exposure and local effects.

Do not use occlusive dressings unless specifically prescribed because occlusion raises potency and systemic absorption.

If other topical agents such as antimicrobials or emollients are used, advise spacing applications and following prescriber or SPC instructions regarding order of application.

• Do not layer steroids with another steroid product.
• Apply emollients at a different time of day when possible.
• Check interactions if the patient is having phototherapy or systemic steroids.

Systemic therapy interactions

When might systemic therapy matter?

Systemic interactions are rare with topical use, but if a patient is receiving systemic corticosteroids or applying potent steroids to large areas, HPA axis effects should be considered and monitored.

Document concurrent systemic steroid therapy on the patient medication record and liaise with the prescriber if needed.

Generics and comparators

Generic mometasone furoate products are expected to be bioequivalent in active ingredient, though excipients and packaging can differ and may affect tolerability or preference.

When switching, compare potency classes: betamethasone and fluticasone occupy a similar potency band, whereas clobetasol is superpotent and reserved for short severe flares and is not a direct equivalent.

Counselling points and when to refer

Essential counselling points

What should every patient know?

Confirm the indication and prescription details and ensure the patient understands to apply a thin layer once daily unless directed otherwise.

Explain likely side effects, the importance of duration limits (typically 1–2 weeks for acute flares), storage at around 25°C and to avoid occlusion unless prescribed.

Highlight not to use on the face or intertriginous areas unless the prescriber has advised, and advise special caution in children and pregnancy.

• Confirm dose and frequency on handover.
• Advise against occlusion and large-area use.
• Provide advice on moisturiser use and hand washing after application.
• Arrange GP/dermatology review if no improvement within 1–2 weeks.

Red flags and referral

When should the pharmacist escalate?

Refer to GP or dermatologist for spreading infection, lack of improvement after the expected timeline, severe local reactions, multiple repeat courses, large-area use in children, pregnancy concerns, or signs of systemic steroid effects.

Delivery across the United Kingdom